Treatment of diabetes mellitus
Rapid Review
| Commenced | Completed | Outcome |
| 17/12/2012 | 04/01/2013 | Full Pharmacoeconomic Assessment Recommended |
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 04/11/2014 | 04/05/2015 | Reimbursement Not Recommended at the submitted price |
December 2015
The HSE has approved reimbursement following confidential price negotiations.
In pharmacoeconomic evaluation, ‘technology’ is used to mean a drug or other treatment that is being assessed.
Period of time over which costs and outcomes are measured in economic evaluation.
Tofacitinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy (i.e. corticosteroids, azathioprine, 6-mercaptopurine) or a biologic agent (i.e. TNF inhibitor).
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 16/07/2018 |
| Rapid review completed | 18/09/2018 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tofacitinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
Jinarc®) to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1-3 at initiation of treatment with evidence of rapidly progressing disease.
| NCPE Assessment Process | Complete |
| Rapid review received | 04/01/2016 |
| Rapid review completed | 12/01/2016 |
| Rapid Review outcome | Full pharmacoeconomic assessment recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 27/01/2017 |
| Full pharmacoeconomic assessment re-commissioned by HSE | 14/08/2017 |
| Pre-submission consultation with applicant | 18/09/2017 |
| Submission received from applicant | 06/02/2018 |
| Preliminary review sent to applicant | 03/04/2018 |
| NCPE assessment re-commenced | 14/05/2018 |
| Preliminary review 2 sent to applicant | 03/07/2018 |
| NCPE assessment recommenced |
23/07/2018 |
| Factual accuracy sent to applicant | 27/08/2018 |
| NCPE assessment recommenced | 06/09/2018 |
| NCPE assessment completed | 13/09/2018 |
| NCPE assessment outcome | The NCPE recommends that tolvaptan not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Goods) Act 2013. |
The probability that the health of a patient changes from one health state to another health state within a given period